Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OGN Stock Forecast 2025-2026
$8.71
Current Price
$2.26B
Market Cap
Buy 2
Hold 3
Sell 2
Wall St Analyst Ratings
Distance to OGN Price Targets
+233.0%
To High Target of $29.00
+72.2%
To Median Target of $15.00
+14.8%
To Low Target of $10.00
OGN Price Momentum
-0.1%
1 Week Change
-22.1%
1 Month Change
-57.3%
1 Year Change
-41.6%
Year-to-Date Change
-62.3%
From 52W High of $23.10
+8.2%
From 52W Low of $8.05
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Organon (OGN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OGN and similar high-potential opportunities.
Latest OGN Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, OGN has a neutral consensus with a median price target of $15.00 (ranging from $10.00 to $29.00). The overall analyst rating is Buy (6.0/10). Currently trading at $8.71, the median forecast implies a 72.2% upside. This outlook is supported by 2 Buy, 3 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by Terence Flynn at Morgan Stanley, suggesting a 14.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OGN Analyst Ratings
2
Buy
3
Hold
2
Sell
OGN Price Target Range
Low
$10.00
Average
$15.00
High
$29.00
Current: $8.71
Latest OGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $10.00 |
| Apr 9, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $15.00 |
| Feb 14, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $24.00 |
| Feb 14, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $16.00 |
| Sep 6, 2024 | JP Morgan | Chris Schott | Underweight | Downgrade | $20.00 |
| May 6, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $20.00 |
| May 3, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $20.00 |
| Apr 29, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $24.00 |
| Feb 20, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $18.00 |
| Nov 22, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $22.00 |
| Nov 3, 2023 | Goldman Sachs | Chris Shibutani | Neutral | Downgrade | $16.00 |
| Oct 25, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $32.00 |
| Oct 11, 2023 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $22.00 |
| Sep 21, 2023 | Barclays | Balaji Prasad | Overweight | Initiates | $28.00 |
| Aug 9, 2023 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $27.00 |
| May 8, 2023 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $25.00 |
| Mar 16, 2023 | Raymond James | Elliot Wilbur | Outperform | Initiates | $33.00 |
| Nov 4, 2022 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $24.00 |
| Oct 14, 2022 | B of A Securities | Jason Gerberry | Underperform | Downgrade | $25.00 |
| Oct 12, 2022 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $27.00 |
Organon & Co. (OGN) Competitors
The following stocks are similar to Organon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Organon & Co. (OGN) Financial Data
Organon & Co. has a market capitalization of $2.26B with a P/E ratio of 3.0x. The company generates $6.29B in trailing twelve-month revenue with a 11.9% profit margin.
Revenue growth is -6.7% quarter-over-quarter, while maintaining an operating margin of +21.5% and return on equity of +254.2%.
Valuation Metrics
Market Cap
$2.26B
Enterprise Value
$10.67B
P/E Ratio
3.0x
PEG Ratio
2.1x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-6.7%
Gross Margin
+55.6%
Operating Margin
+21.5%
Net Margin
+11.9%
EPS Growth
-56.7%
Financial Health
Cash/Price Ratio
+24.2%
Current Ratio
1.7x
Debt/Equity
1,652.4x
ROE
+254.2%
ROA
+7.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Organon & Co. (OGN) Business Model
About Organon & Co.
What They Do
Global healthcare company focused on women's health.
Business Model
Organon & Co. generates revenue through the discovery, development, manufacture, and commercialization of therapeutic solutions, particularly aimed at women's health. The company focuses on family planning and fertility products while also offering a range of hormone replacement therapies and biosimilars.
Additional Information
Founded as a standalone entity in 2021 after being spun off from Merck & Co., Organon targets underserved markets and leverages its pharmaceutical expertise to address unique health needs. Its strategic focus on women's health positions it well within the healthcare sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
10,000
CEO
Mr. Kevin Ali
Country
United States
IPO Year
2021
Website
www.organon.comOrganon & Co. (OGN) Latest News & Analysis
Latest News
Quick Summary
Robbins Geller Rudman & Dowd LLP is investigating Organon & Co. (NYSE: OGN) for potential violations of federal securities laws related to false statements and undisclosed information.
Why It Matters
Potential legal issues for Organon & Co. could lead to stock price volatility and impact investor confidence, affecting investment decisions and market perception.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Organon reported a significant decline in Q1 2025 earnings, leading to a 30% drop in share price after a >90% dividend cut due to shrinking sales and patent expirations.
Why It Matters
Organon's sharp earnings decline and dividend cut signal financial instability, raising concerns about its revenue generation and future growth, impacting investor confidence and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Bragar Eagel & Squire is investigating Organon & Co. (NYSE: OGN) for potential violations of federal securities laws and unlawful business practices on behalf of its stockholders.
Why It Matters
Legal investigations can lead to stock volatility, potential financial penalties, or reputational damage for Organon, impacting shareholder value and investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors of Organon & Co. (NYSE: OGN). Affected investors can seek more information at bgandg.com/OGN.
Why It Matters
The investigation into Organon could indicate potential legal issues or financial irregularities, impacting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating Organon & Co. (NYSE: OGN) for potential federal securities law violations following its Q1 FY25 results, which showed a 7% revenue decline to $1.51B.
Why It Matters
Organon's investigation for potential securities law violations following disappointing Q1 results may signal increased risk, impacting stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Organon & Co. (NYSE: OGN). Affected investors can find more information at bgandg.com/OGN.
Why It Matters
The investigation into Organon & Co. may indicate potential legal issues, impacting stock performance and investor confidence, leading to volatility in share prices.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About OGN Stock
What is Organon & Co.'s (OGN) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Organon & Co. (OGN) has a median price target of $15.00. The highest price target is $29.00 and the lowest is $10.00.
Is OGN stock a good investment in 2025?
According to current analyst ratings, OGN has 2 Buy ratings, 3 Hold ratings, and 2 Sell ratings. The stock is currently trading at $8.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OGN stock?
Wall Street analysts predict OGN stock could reach $15.00 in the next 12 months. This represents a 72.2% increase from the current price of $8.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Organon & Co.'s business model?
Organon & Co. generates revenue through the discovery, development, manufacture, and commercialization of therapeutic solutions, particularly aimed at women's health. The company focuses on family planning and fertility products while also offering a range of hormone replacement therapies and biosimilars.
What is the highest forecasted price for OGN Organon & Co.?
The highest price target for OGN is $29.00 from at , which represents a 233.0% increase from the current price of $8.71.
What is the lowest forecasted price for OGN Organon & Co.?
The lowest price target for OGN is $10.00 from Terence Flynn at Morgan Stanley, which represents a 14.8% increase from the current price of $8.71.
What is the overall OGN consensus from analysts for Organon & Co.?
The overall analyst consensus for OGN is neutral. Out of 9 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 2 as Sell, with a median price target of $15.00.
How accurate are OGN stock price projections?
Stock price projections, including those for Organon & Co., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 10:40 AM UTC